Security key
87978U108
Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (TPST)
CUSIP: 87978U108
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 14,815,636
- Total 13F shares
- 269,772
- Share change
- -2,210,036
- Total reported value
- $1,834,450
- Price per share
- $6.80
- Number of holders
- 1
- Value change
- +$4,501
- Number of buys
- 1
- Number of sells
- 21
Report period
Q2 2025
Institutions
1
Top holders
1
TPST full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Tempest Therapeutics, Inc. SEC filings
Tempest Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87978U108
Recent filing periods:
Top shareholders of TPST - Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Versant Venture Management, LLC |
13F
|
Company |
26%
|
3,507,055
|
$2,588,207 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
3.8%
|
561,503
|
$414,389 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.9%
|
433,346
|
$319,827 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
2.9%
|
431,932
|
$318,766 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
2.2%
|
323,699
|
$238,890 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
297,877
|
$219,833 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.77%
|
114,559
|
$84,545 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.67%
|
99,391
|
$73,351 | — | 31 Mar 2025 | |
| DAVENPORT & Co LLC |
13F
|
Company |
0.34%
|
50,000
|
$36,900 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.3%
|
44,465
|
$32,815 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.28%
|
41,492
|
$30,621 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.17%
|
25,722
|
$19,018 | — | 31 Mar 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.14%
|
20,422
|
$15,000 | — | 31 Mar 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.13%
|
20,000
|
$14,660 | — | 31 Mar 2025 | |
| MayTech Global Investments, LLC |
13F
|
Company |
0.07%
|
10,000
|
$7,380 | — | 31 Mar 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0.03%
|
3,800
|
$2,804 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
767
|
$566 | — | 31 Mar 2025 | |
| Millstone Evans Group, LLC |
13F
|
Company |
0.01%
|
800
|
$590 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
349
|
$258 | — | 31 Mar 2025 | |
| Parallel Advisors, LLC |
13F
|
Company |
0%
|
236
|
$174 | — | 31 Mar 2025 | |
| CIBC Private Wealth Group LLC |
13F
|
Company |
0%
|
133
|
$67 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
77
|
$57 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
48
|
$35 | — | 31 Mar 2025 | |
| Versant Vantage II, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,118,644
|
$10,127,118 | — | 29 Apr 2022 | |
| Versant Venture Capital VI, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,328,585
|
$2,562,608 | — | 08 Aug 2024 | |
| Rock Springs Capital Management LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
73,654
|
$352,066 | — | 30 Dec 2021 | |
| Stephen R. Brady |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
596,376
mixed-class rows
|
$97,853 | — | 02 Jan 2025 | |
| Samuel Whiting |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
279,573
mixed-class rows
|
$20,390 | — | 02 Jan 2025 | |
| Thomas W. Dubensky |
3/4/5
|
President, Director |
—
class O/S missing
|
102,700
|
— | — | 03 Jan 2023 | |
| Pierre Lorenzo |
3/4/5
|
Corporate Controller |
—
class O/S missing
|
8,477
|
— | — | 21 Jun 2022 | |
| Stella Xu |
3/4/5
|
Director |
—
class O/S missing
|
6,635
|
— | — | 01 Jul 2021 | |
| Thomas Woiwode |
3/4/5
|
Director |
—
class O/S missing
|
3,500
|
— | — | 17 Jun 2022 |
Institutional Holders of Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (TPST) as of Q2 2025
As of 30 Jun 2025,
Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (TPST) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
269,772 shares.
The largest 1 holders included
Versant Venture Management, LLC.
This page lists
1
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
21
Q2 2025 holders
1
Holder diff
-20
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.